XML 132 R47.htm IDEA: XBRL DOCUMENT
v3.22.1

Commitments and Contingencies (Details Narrative) |  |  |  |  |  |  |  |  | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 04, 2022 USD ($) | Mar. 03, 2022 USD ($) | Dec. 29, 2021 USD ($) | Dec. 02, 2021 USD ($) | Nov. 19, 2021 ft² | Aug. 06, 2021 USD ($) | Mar. 26, 2021 USD ($) | Oct. 05, 2020 | Mar. 31, 2021 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |
Project fees |  |  |  |  |  |  |  |  |  |  | $ 2,100,000
Initial payment |  |  | $ 191,527 | $ 541,527 |  |  |  |  |  |  |
Periodic payment to be made |  |  |  |  |  |  |  |  |  |  | 191,527
Final payment |  |  |  |  |  |  |  |  |  |  | 192,470
Other Commitments, Description |  |  |  |  |  |  |  | On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At December 31, 2021, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $7.5 million was incurred at that date and an additional $5.5 million is in process during fiscal year 2022. |  |  |
Received upfront payment |  |  |  |  |  |  |  |  |  |  | 200,000
Annual maintanance fee |  |  |  |  |  |  |  |  |  |  | $ 100,000
Royalty fee percentage |  |  |  |  |  |  |  |  |  |  | 0.04
Annual royalty payments |  |  |  |  |  |  |  |  | $ 250,000 |  |
Performance milestone payments |  |  |  |  |  |  |  |  | 3,100,000 |  | $ 3,100,000
Sales milestone payments |  |  |  |  |  |  |  |  | 1.0 |  | 1,000,000.0
Gross sales |  |  |  |  |  |  |  |  | 250,000,000 |  | 250,000,000
Sales revenue |  |  |  |  |  |  |  |  | 5.0 | $ 5.0 |
Cummulative gross sales |  |  |  |  |  |  |  |  | 500,000,000 | $ 500 |
Upfront license fee |  |  |  |  |  |  | $ 20,000 |  |  |  |
License maintenance fee, receivable |  |  |  |  |  |  |  |  |  |  | 5,000
[custom:MaintananceFee] |  |  |  |  |  |  |  |  | $ 2.0 |  |
Aimmune Therapeutics Inc [Member] |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |
Area of Land | ft² |  |  |  |  | 4,500 |  |  |  |  |  |
Lessee, Operating Sublease, Option to Extend |  |  |  |  | commencement date of January 1, 2022 and maturing on June 30, 2024 |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |
Annual royalty payments |  |  |  |  |  |  |  |  |  |  | 250,000
[custom:NetSalesPercentage] |  |  |  |  |  |  |  |  | 0.025 |  |
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |
[custom:NetSalesPercentage] |  |  |  |  |  |  |  |  | 0.05 |  |
Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |
Commitment amount for services, total |  |  |  |  |  |  |  |  |  |  | 13,000,000.0
Commitment cost incurred |  |  |  |  |  |  |  |  |  |  | 7,500,000
Compensation cost expected to be incurred in future |  |  |  |  |  |  |  |  |  |  | $ 5,500,000
Sheffield Properties [Member] |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement, Expense |  |  |  |  |  | $ 100,000 |  |  |  |  |
Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement, Expense | $ 425,000,000,000 | $ 400,000 |  |  |  |  |  |  |  |  |

X
- Definition Annual maintanance fee. + References No definition available. + Details
Name: | GTBP_AnnualMaintananceFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_AnnualRoyaltyPayments
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_CummulativeGrossSales
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_FinalPayment
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_GrossSales
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_InitialPayment
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License maintenance fee, receivable. + References No definition available. + Details
Name: | GTBP_LicenseMaintenanceFeeReceivable
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | GTBP_MaintananceFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_NetSalesPercentage
Namespace Prefix: | GTBP_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_PerformanceMilestonePayments
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Quarterly payments to be made. + References No definition available. + Details
Name: | GTBP_PeriodicPaymentToBeMade
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Received upfront payment. + References No definition available. + Details
Name: | GTBP_ProceedsFromUpfrontAmount
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | GTBP_ProjectFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Compensation cost expected to be incurred in future. + References No definition available. + Details
Name: | GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_RoyaltyFeePercentage
Namespace Prefix: | GTBP_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_SalesMilestonePayments
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | GTBP_SalesRevenue
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront license fee. + References No definition available. + Details
Name: | GTBP_UpfrontLicenseFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Area of land held. + References No definition available. + Details
Name: | us-gaap_AreaOfLand
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:areaItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of terms and conditions of option to extend operating sublease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeOperatingSubleaseOptionToExtend
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the nature and terms of commitment. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=GTBP_AimmuneTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=GTBP_CytovanceBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_SheffieldPropertiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |